PSG-102
Focal Onset Seizures (Epilepsy)
Phase 2Active
Key Facts
About PharmaSGP
PharmaSGP is a clinical-stage biopharmaceutical company headquartered in Germany with a strategic focus on neurological and rare disease therapeutics. The company has built a diversified pipeline of novel drug candidates, primarily in Phase 2 development, targeting conditions such as Parkinson's disease, epilepsy, and rare genetic disorders. With a public listing providing financial stability, PharmaSGP combines scientific innovation with commercial execution to address complex medical challenges in specialized therapeutic areas.
View full company profileTherapeutic Areas
Other Focal Onset Seizures (Epilepsy) Drugs
| Drug | Company | Phase |
|---|---|---|
| XEN1101 | Xenon Pharmaceuticals | Phase 3 |